Results 101 to 110 of about 492,703 (122)

Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study

Lancet, The, 2013
Carlo Torti, Chloe Orkin, Mark Bloch
exaly  

Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial

Lancet, The, 2007
Jose M Gatell, Adriano Lazzarin
exaly  

Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials

Lancet, The, 2010
Joseph J Eron, Benjamin Young, Michael D Miller   +2 more
exaly  

Discovery of Raltegravir, a Potent, Selective Orally Bioavailable HIV-Integrase Inhibitor for the Treatment of HIV-AIDS Infection

Journal of Medicinal Chemistry, 2008
Cristina Gardelli, Michael Rowley
exaly  

HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects

Nature Medicine, 2010
Marta Massanella, Viktor Dahl, Maria C Puertas   +2 more
exaly  

Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study

Journal of Infectious Diseases, 2014
Antonella Castagna, Franco Maggiolo, Anthony M Mills   +2 more
exaly  

Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study

Journal of Infectious Diseases, 2013
Joseph J Eron, Bonaventura Clotet, Adriano Lazzarin   +2 more
exaly  

Development and Validation of RP-HPLC and HPTLC Chromatographic Methods of Analysis for the Quantitative Estimation of Raltegravir Potassium in Pharmaceutical Dosage Form

, 2011
T. Sudha, P. Shanmugasundram
openalex  

Body Composition Changes After Initiation of Raltegravir or Protease Inhibitors: ACTG A5260s

Clinical Infectious Diseases, 2016
Grace A Mccomsey, Carlee Moser, Theodoros Kelesidis   +2 more
exaly  

Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial

Lancet Infectious Diseases, The, 2011
Joseph J Eron, Linda-Gail Bekker, Jose R Arribas   +2 more
exaly